BIOMAT Database Logo BIOMAT Database Logo

Antiviral agents 3. Discovery of a novel small molecule non-nucleoside inhibitor of hepatitis B virus (HBV). 2011

Ian T Crosby, and David G Bourke, and Eric D Jones, and Tyrone P Jeynes, and Susan Cox, and Jonathan A V Coates, and Alan D Robertson
Medicinal Chemistry and Drug Action, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. ian.crosby@monash.edu

The discovery of a small molecule non-nucleoside inhibitor of Hepatitis B Virus is described. During our work on conocurvone derived naphthoquinone 'trimers' for the treatment of HIV, we discovered a potent inhibitor 9 of Hepatitis B Virus in an antiviral screen. During attempts to resynthesis 9 for proof of concept studies, we altered the synthesis in order to attempt to reduced side reactions and difficult to remove by-products. As a result we discovered a small molecule 19 that also was a potent inhibitor of HBV. Importantly, this small molecule inhibitor of Hepatitis B Virus is also an inhibitor of Hepatitis B Virus resistant to 3TC, a bench mark of nucleoside analogues active in the treatment of Hepatitis B Virus. The development of 19 as an agent to treat HBV infections is discussed.

UI MeSH Term Description Entries
D006515 Hepatitis B virus The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum. Dane Particle,Hepatitis Virus, Homologous Serum,B virus, Hepatitis,Hepatitis B viruses,Particle, Dane,viruses, Hepatitis B
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D055808 Drug Discovery The process of finding chemicals for potential therapeutic use. Drug Prospecting,Discovery, Drug,Prospecting, Drug

Related Publications

Ian T Crosby, and David G Bourke, and Eric D Jones, and Tyrone P Jeynes, and Susan Cox, and Jonathan A V Coates, and Alan D Robertson
Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus.
January 2022, PloS one,
Ian T Crosby, and David G Bourke, and Eric D Jones, and Tyrone P Jeynes, and Susan Cox, and Jonathan A V Coates, and Alan D Robertson
A review of non-nucleoside anti-hepatitis B virus agents.
March 2014, European journal of medicinal chemistry,
Ian T Crosby, and David G Bourke, and Eric D Jones, and Tyrone P Jeynes, and Susan Cox, and Jonathan A V Coates, and Alan D Robertson
A novel small molecule inhibitor of hepatitis C virus entry.
September 2010, PLoS pathogens,
Ian T Crosby, and David G Bourke, and Eric D Jones, and Tyrone P Jeynes, and Susan Cox, and Jonathan A V Coates, and Alan D Robertson
Antiviral properties of 3-quinolinecarboxamides: a series of novel non-nucleoside antiherpetic agents.
May 1997, Drug design and discovery,
Ian T Crosby, and David G Bourke, and Eric D Jones, and Tyrone P Jeynes, and Susan Cox, and Jonathan A V Coates, and Alan D Robertson
Antiviral treatment of chronic hepatitis B virus (HBV) infections.
June 2010, Viruses,
Ian T Crosby, and David G Bourke, and Eric D Jones, and Tyrone P Jeynes, and Susan Cox, and Jonathan A V Coates, and Alan D Robertson
Ceestatin, a novel small molecule inhibitor of hepatitis C virus replication, inhibits 3-hydroxy-3-methylglutaryl-coenzyme A synthase.
August 2011, The Journal of infectious diseases,
Ian T Crosby, and David G Bourke, and Eric D Jones, and Tyrone P Jeynes, and Susan Cox, and Jonathan A V Coates, and Alan D Robertson
In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus.
April 1994, Antimicrobial agents and chemotherapy,
Ian T Crosby, and David G Bourke, and Eric D Jones, and Tyrone P Jeynes, and Susan Cox, and Jonathan A V Coates, and Alan D Robertson
The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication.
November 2011, Antiviral research,
Ian T Crosby, and David G Bourke, and Eric D Jones, and Tyrone P Jeynes, and Susan Cox, and Jonathan A V Coates, and Alan D Robertson
Design, synthesis and evaluation against Chikungunya virus of novel small-molecule antiviral agents.
February 2018, Bioorganic & medicinal chemistry,
Ian T Crosby, and David G Bourke, and Eric D Jones, and Tyrone P Jeynes, and Susan Cox, and Jonathan A V Coates, and Alan D Robertson
[Discovery of a hepatitis non-A-non-B virus].
August 1989, Zeitschrift fur Gastroenterologie,
Copied contents to your clipboard!